Launch of generic Farxiga (Dapagliflozin Propanediol tablets)

The generic formulation of Farxiga, Dapagilflozin Propanediol tablets has been recently release. 

DAPAGLIFLOZIN TABLETS are indicated: 

• To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. 

• To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. 

• To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. 

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 

Dapagliflozin Propanediol tablets are manufactured by Prasco Laboratories. It is available in 5mg and 10mg tablets.